Prevention & lipidsMeta-analysis
Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events
- Systematic review and meta-analysis
- dose-response meta-analysis
- random-effects
Authors' conclusion
As few as about 2,600 and about 2,800 steps/d yield significant mortality and CVD benefits, with progressive risk reductions up to about 8,800 and about 7,200 steps/d, respectively. Additional mortality benefits were found at a moderate to high vs a low step cadence.
Study context
- Population
- General population with objectively measured step counts
- Participants
- 111,309 participants · 12 studies
- Comparison
- Daily step counts vs 2,000 steps/d
- Outcome
- All-cause mortality and incident cardiovascular disease (CVD)
Pooled result
As reported in the abstract
Each group vs 2,000 steps/dAdjusted hazard ratio (95% CI)
2,517 steps/dall-cause mortality; minimal significant dose
0.92(0.84–0.999)
2,735 steps/dincident CVD; minimal significant dose
0.89(0.79–0.999)
8,763 steps/dall-cause mortality; optimal dose
0.40(0.38–0.43)
7,126 steps/dincident CVD; optimal dose
0.49(0.45–0.55)
Further pooled results
Step cadence and all-cause mortality
- Increments from low to intermediate or high cadence independently associated with lower all-cause mortality
Dose-response by sex, device and wear location (subgroups)
- Sex did not influence the dose-response associations
- Pronounced risk reductions for hip-worn accelerometers vs pedometers and wrist-worn accelerometers
Original publication
Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events. J Am Coll Cardiol. Published 6 September 2023. doi:10.1016/j.jacc.2023.07.029
Summarised from the published abstract; every number is checked against it